CN1446554A - Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method - Google Patents
Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method Download PDFInfo
- Publication number
- CN1446554A CN1446554A CN 02109347 CN02109347A CN1446554A CN 1446554 A CN1446554 A CN 1446554A CN 02109347 CN02109347 CN 02109347 CN 02109347 A CN02109347 A CN 02109347A CN 1446554 A CN1446554 A CN 1446554A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- acute
- chronic cholecystitis
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating acute and chronic cholecystitis is prepared from 8 Chinese-medicinal materials including bear gall powder, scutellaria root, bupleurum root, oriental wormwood, etc. Its advantages are high curative effect and no recurrence.
Description
Technical field: the present invention relates to a kind of medicine for the treatment of acute and chronic cholecystitis.Be the Chinese patent medicine of feedstock production specifically, the invention still further relates to the preparation method of this medicine with Chinese medicine.
Background technology: acute and chronic cholecystitis is present commonly encountered diseases clinically, and morbidity in recent years has the trend that increases year by year.Its cardinal symptom is the frequent pain of right abdominal part, inappetence, bitter taste in the mouth and dry throat, and hyperpyrexia, jaundice appear in weight person, back part severe pain, and the patient is very painful, has a strong impact on the normal live and work of patient.
At present many gentamycin antibiotics class medicine can only be alleviated surface symptoms to the medicine of state's internal therapy primary disease based on simple antiinflammatory, and curative effect is undesirable, and drug withdrawal easily recurs, and the patient must not take medicine for a long time and keep, and is easy to generate Drug resistance.And the excision gallbladder is not suitable for older and is associated with the patient of other organ disease.So this disease of treatment by Chinese herbs of inventing a kind for the treatment of both the principal and secondary aspects of a disease has become the fervent expectation of extensive patients.
Summary of the invention: the object of the present invention is to provide a kind ofly to have antiinflammatory, analgesic, pain relieving, inhibition calculi in vivo and form, cholesterol reducing reduces capillary permeability, reduces cholecystitis medicine of cholecystitis complication effect and preparation method thereof
Above-mentioned purpose realizes by following technical scheme:
A kind of medicine for the treatment of acute and chronic cholecystitis, the Chinese medicine preparation that it is made by the following weight proportion raw material.
Fel Ursi powder 2～15 Radix Scutellariaes 30～60 Radix Bupleuri 30～50
Herba Artemisiae Scopariae 55～65 Herba Lysimachiaes 50～65 Radix Curcumaes 5～20
Fructus Toosendan 5～20 Rhizoma Cyperis 35～50.
The medicine of the acute and chronic cholecystitis of described treatment, wherein the weight proportion of each raw material is:
Fel Ursi powder 5 Radix Scutellariaes 50 Radix Bupleuri 41.5 Herba Artemisiae Scopariaes 62.5
Herba Lysimachiae 62.5 Radix Curcumaes 10 Fructus Toosendans 10 Rhizoma Cyperis 41.5.
The medicine of the acute and chronic cholecystitis of described treatment, said medicament are said dosage forms on any pharmaceutics.
The medicine of the acute and chronic cholecystitis of described treatment, said medicament are tablet, capsule, granule, oral liquid, injection.
The preparation method of the medicine of the acute and chronic cholecystitis of described treatment:
Get Radix Curcumae earlier, powder becomes fine powder; Radix Scutellariae drops into boiling water, decocts three times, is concentrated into relative density 1.05～1.08 (80 ℃), adds hydrochloric acid and transfers PH to 1～2, leaves standstill, and precipitation is dry, pulverizing is standby.Five kinds of Chinese medicine such as Herba Lysimachiae, Fructus Toosendan, Radix Bupleuri, Herba Artemisiae Scopariae, Rhizoma Cyperi decoct with water twice, being concentrated into relative density is the clear paste of 1.18～1.22 (80 ℃), adds ethanol and reaches 60% to containing the alcohol amount, filters, filtrate recycling ethanol is concentrated into the extractum of relative density 1.32～1.34 (60 ℃).Get Fel Ursi powder, Radix Curcumae fine powder, Radix Scutellariae extract and add in the above-mentioned extractum, mixing, cold drying, powder becomes fine powder, granulates, and makes tablet, capsule, granule, oral liquid, injection.
This technical scheme has following beneficial effect:
One, through Clinical Laboratory, this product obviously has antiinflammatory, analgesic, pain relieving, inhibition calculi in vivo and forms, and the effect of cholesterol reducing for reducing capillary permeability, reduces the cholecystitis complication and has significant effect.
Two, this product is a kind of Chinese medicine for the treatment of both the principal and secondary aspects of a disease, and long-term effect is good, and is evident in efficacy, and is difficult for recurrence after the drug withdrawal, and the patient does not take medicine for a long time at needs and keeps, and does not develop immunity to drugs.Avoided the misery of excision gallbladder, evoke complication cause other organ disease.
Three, medicine of the present invention has certain curative effect through the evidence safety non-toxic to acute and chronic cholecystitis, and its toxicology and pharmacodynamic experiment data are as follows:
1, give mouse stomach with Cmax and the maximum gastric capacity of irritating, per 8 hours once, every day three times, observes in the administration 24 hours and afterwards 7 days: tried mice and death and other abnormal response do not occur.It is 165.22g/kg/ day that experiment records the mice maximum tolerated dose, is 394.73 times of the clinical adult of this medicine consumption every day (, add up to crude drug 20.928g/kg body weight every day 3 times by each 4).The consumption per day that shows medicine of the present invention is safe.
2, long term toxicity test: respectively with 0.9g/kg, 4.5g/kg (symphysis medicine 4.13g/kg, 20.65g/kg) gives the administration of Wistar rat oral gavage, once a day, continuous irrigation stomach 60 days, result of the test shows that general state, behavioral activity and the diet situation and the matched group that are tried rat do not have significant difference; Hematology, liver function, renal function and organ coefficient and matched group more all do not have significant difference, show that it is safe taking medicine of the present invention for a long time.
3, to the influence of rabbit cholelithiasis due to the dihydrocholesterol
In feedstuff, sneak into dihydrocholesterol (1%), give around the continuous nursing of rabbit, every day while, gastric infusion was 1 time, matched group is given and cholagogic and lithagogue tablet, model control group is given and normal saline with volume, around the successive administration, measured the cholesterol level in serum and the bile in 24 hours after the last administration, result of the test sees Table 1.
The influence of rabbit cholelithiasis model serum and bile cholesterol due to the table 1 pair dihydrocholesterol
Chol content (mmol/l) in chol content (mmol/l) bile in the group dosage number of animals serum
(g/kg) (only) (X ± SD) (X ± SD) the heavy dose of group 0.547 8 3.10 ± 0.74 6.30 ± 3.10 of examination is tested middle dosage group 0.273 8 5.31 ± 0.89 7.18 ± 2.85 medicine small dose group 0.137 8 6.04 ± 1.01 9.41 ± 3.05
Cholagogic and lithagogue tablet 0.270 8 5.18 ± 0.94 10.71 ± 2.98
Normal saline is with volume 8 8.25 ± 1.32 15.72 ± 3.85
The result shows: medicine of the present invention may obviously reduce the cholesterol level (P＜0.01) that raises in the rabbit anteserum and bile due to the dihydrocholesterol.
The influence of rabbit cholesterol calculus due to the table 2 pair dihydrocholesterol
Group dosage number of animals cholelithiasis incidence rate P value
(g/kg) (only) (%)
The heavy dose of group 0.547 8 25.00＜0.05 of examination
Dosage group 0.273 8 37.50＞0.05 in testing
Medicine small dose group 0.137 8 62.50＞0.05
Cholagogic and lithagogue tablet 0.270 8 37.50＞0.05
Normal saline is with volume 8 37.50
The result shows: medicine of the present invention is to the obvious suppression effect that is formed with of rabbit cholesterol calculus due to the dihydrocholesterol.
4, the influence of xylol induced mice inflammatory capillary permeability increase:
Get three variable concentrations of medicine of the present invention every days once to mouse stomach, successive administration three days, positive control drug are cholagogic and lithagogue tablet, chlorpheniramine maleate tablets, and the blank group is given the normal saline with volume, after the last administration 60 minutes, record after getting the organized processing that mice two ears symmetries area equates:
The influence that table 3 pair mice dimethylbenzene inflammatory capillary permeability increases
Group dosage number of animals OD value P value
(g/kg) (only) (X ± SD)
The heavy dose of group 2.188 10 0.030 ± 0.01＜0.01 of examination
Dosage group 1.094 10 0.035 ± 0.01＜0.01 in testing
Medicine small dose group 0.547 10 0.050 ± 0.02＜0.01
Cholagogic and lithagogue tablet 1.080 10 0.040 ± 0.02＜0.01
Chlorphenamine 0.050 10 0.025 ± 0.01＜0.01
Normal saline is with volume 10 0.18 ± 0.02
Do not cause scorching normal mouse 10 0.11 ± 0.01＜0.01
The result shows: medicine xylol inflammatory capillary permeability of the present invention increase has the antagonism (P＜0.01) of highly significant.
5, the influence of Dichlorodiphenyl Acetate induced mice Ovum Gallus domesticus album foot swelling
Get the large, medium and small dosage of trial drug, give rat oral gavage once every day, successive administration three days, after the last administration immediately feedwater load after 30 minutes in every the right back ankle subcutaneous injection of rat fresh egg white 0.1ml, measuring the ankle joint girth with tape respectively, is the swollen joint expansibility with the difference of left and right sides ankle joint girth.
The influence of foot swelling due to the table 4 pair rat Ovum Gallus domesticus album
The group dosage number of animals paw swelling (mm of X ± SD)
(g/kg), dosage group 0.638 10 4.7 ± 1.1 4.5 ± 1.2 4.3 ± 1.2 4.3 ± 1.0 3.9 ± 1.3 medicine small dose group 0.319 10 4.7 ± 1.2 4.8 ± 1.0 4.8 ± 1.3 4.5 ± 1.3 4.0 ± 1.5 during the heavy dose of group 1.276 10 4.5 ± 1.5 4.3 ± 1.6 3.9 ± 1.0 3.4 ± 0.9 3.0 ± 0.9 of (only) 0.5h 1h 2h 4h 6h examination is tested
Cholagogic and lithagogue tablet 0.630 10 4.8 ± 1.1 4.9 ± 1.4 4.6 ± 1.2 4.0 ± 1.1 3.9 ± 1.1
Dexamethasone 0.030 10 4.2 ± 1.1 4.0 ± 1.3 3.8 ± 1.2 3.0 ± 0.6 2.3 ± 0.8
Normal saline is with volume 10 6.3 ± 1.4 6.4 ± 1.2 6.0 ± 1.8 5.6 ± 1.4 5.0 ± 1.2
The result shows: foot swelling has the obvious suppression effect to medicine of the present invention to rat Ovum Gallus domesticus album.
6, the influence of Dichlorodiphenyl Acetate induced mice writhing response
Get large, medium and small three variable concentrations of medicine of the present invention, give the mouse stomach administration respectively, once a day, successive administration three days, 1 hour every mouse peritoneal is injected 0.7% acetic acid after the last administration, mouse writhing number of times in 20 minutes behind the record injection acetic acid.
The influence of table 5 Dichlorodiphenyl Acetate induced mice writhing response
Turn round body number (inferior) P value in the 20min behind the group dosage number of animals notes acetic acid
(g/kg) (only) (dosage group 1.094 10 20.13 ± 13.41＜0.01 medicine small dose group 0.547 10 26.74 ± 16.58＜0.05 during X ± SD) the heavy dose of group 2.188 10 17.23 ± 10.92＜0.01 of examination is tested
Cholagogic and lithagogue tablet 1.080 10 25.17 ± 13.94＜0.01
Rotundine 0.060 10 13.18 ± 10.92＜0.01
Normal saline is with volume 10 49.56 ± 21.23
The result shows: the writhing response of medicine Dichlorodiphenyl Acetate induced mice of the present invention has significant antagonism (P＜0.01).
The main pharmacodynamics result of study shows: medicine of the present invention has the cholelithiasis of inhibition and forms antiinflammatory, analgesic activity.
Embodiment 1:
A kind of medicine for the treatment of acute and chronic cholecystitis is characterized in that the Chinese medicine preparation that it is made by the following weight proportion raw material.
Fel Ursi powder 2～15 Radix Scutellariaes 30～60 Radix Bupleuri 30～50
Herba Artemisiae Scopariae 55～65 Herba Lysimachiaes 50～65 Radix Curcumaes 5～20
Fructus Toosendan 5～20 Rhizoma Cyperis 35～50.
Embodiment 2:
The medicine of the acute and chronic cholecystitis of embodiment 1 described treatment, wherein the weight proportion of each raw material is with kilogram:
Fel Ursi powder 2 or 10 or 15, Radix Scutellariae 30 or 40 or 50 or 60, Radix Bupleuri 30 or 40 or 50, Herba Artemisiae Scopariae 55 or 60 or 65, Herba Lysimachiae 50 or 55 or 60 or 65 Radix Curcumaes 5 or 10 or 15 or 20, Fructus Toosendan 5 or 10 or 15 or 20, Rhizoma Cyperi 35 or 40 or 45 or 50.
Embodiment 3:
The medicine of the above-mentioned acute and chronic cholecystitis of treatment, wherein the weight proportion of each raw material is:
Fel Ursi powder 5 Radix Scutellariaes 50 Radix Bupleuri 41.5 Herba Artemisiae Scopariaes 62.5
Better effects if during Herba Lysimachiae 62.5 Radix Curcumaes 10 Fructus Toosendans 10 Rhizoma Cyperis 41.5.
The medicine of the above-mentioned acute and chronic cholecystitis of treatment, said medicament are said dosage forms on any pharmaceutics, comprise tablet, capsule, granule, oral liquid, injection or the like.
Embodiment 4:
Medicine of the present invention is to make (consumption is a weight portion) by following component:
Fel Ursi powder 2～15 Radix Scutellariaes 30～60 Radix Bupleuri 30～50
Herba Artemisiae Scopariae 55～65 Herba Lysimachiaes 50～65 Radix Curcumaes 5～20
Fructus Toosendan 5～20 Rhizoma Cyperis 35～50
The optimum weight of medicine of the present invention (part) proportioning is:
Fel Ursi powder 5 Radix Scutellariaes 50 Radix Bupleuri 41.5 Herba Artemisiae Scopariaes 62.5
Herba Lysimachiae 62.5 Radix Curcumaes 10 Fructus Toosendans 10 Rhizoma Cyperis 41.5
Above-mentioned each component is made medicine production method of the present invention is:
1. turmeric powder is become fine powder;
2. Radix Scutellariae drops in the boiling water and decocts, and medicinal residues discard, and extracting solution is concentrated into the clear paste shape, and adding hydrochloric acid is transferred pH value to 1～2, leaves standstill, and filters, and precipitation is dry, pulverizing is standby;
3. Herba Lysimachiae, Fructus Toosendan, Herba Artemisiae Scopariae, Radix Bupleuri, Rhizoma Cyperi five kinds of Chinese medicine extracting in water, medicinal residues discard, and extracting solution is concentrated into the clear paste shape, adds ethanol and reaches 60% to containing the alcohol amount, filters, and filtrate recycling ethanol also is concentrated into the extractum that relative density is 1.33～1.34 (60 ℃);
4. Fel Ursi powder, Radix Curcumae fine powder, Radix Scutellariae extract add in the above-mentioned clear paste, mixing, and drying, powder becomes fine powder, adds suitable adjuvant, makes corresponding granule, tablet, capsule, or further makes oral liquid, injection.
Usage and consumption: oral, one time 4,3 times on the one.
Claims (5)
1. the medicine of the acute and chronic cholecystitis of treatment is characterized in that the Chinese medicine preparation that it is made by the following weight proportion raw material.
Fel Ursi powder 2～15 Radix Scutellariaes 3060 Radix Bupleuri 30～50
Herba Artemisiae Scopariae 55～65 Herba Lysimachiaes 50～65 Radix Curcumaes 5～20
Fructus Toosendan 5～20 Rhizoma Cyperis 35～50.
2. the medicine of the acute and chronic cholecystitis of treatment according to claim 1 is characterized in that, wherein the weight proportion of each raw material is:
Fel Ursi powder 5 Radix Scutellariaes 50 Radix Bupleuri 41.5 Herba Artemisiae Scopariaes 62.5
Herba Lysimachiae 62.5 Radix Curcumaes 10 Fructus Toosendans 10 Rhizoma Cyperis 41.5.
3. the medicine of the acute and chronic cholecystitis of treatment according to claim 1 and 2 is characterized in that said medicament is a said dosage form on any pharmaceutics.
4. the medicine of the acute and chronic cholecystitis of treatment according to claim 3 is characterized in that said medicament is tablet, capsule, granule, oral liquid, injection.
5. the preparation method of the medicine of a claim 1, the acute and chronic cholecystitis of 2,3 or 4 described treatments is characterized in that:
Get Radix Curcumae earlier, powder becomes fine powder; Radix Scutellariae drops into boiling water, decocts three times, is concentrated into relative density 1.05～1.08 (80 ℃), adds hydrochloric acid and transfers PH to 1～2, leaves standstill, and precipitation is dry, pulverizing is standby.Five kinds of Chinese medicine such as Herba Lysimachiae, Fructus Toosendan, Radix Bupleuri, Herba Artemisiae Scopariae, Rhizoma Cyperi decoct with water twice, being concentrated into relative density is the clear paste of 1.18～1.22 (80 ℃), adds ethanol and reaches 60% to containing the alcohol amount, filters, filtrate recycling ethanol is concentrated into the extractum of relative density 1.32～1.34 (60 ℃).Get Fel Ursi powder, Radix Curcumae fine powder, Radix Scutellariae extract and add in the above-mentioned extractum, mixing, cold drying, powder becomes fine powder, granulates, and makes tablet, capsule, granule, oral liquid, injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02109347 CN1261151C (en) | 2002-03-24 | 2002-03-24 | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02109347 CN1261151C (en) | 2002-03-24 | 2002-03-24 | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1446554A true CN1446554A (en) | 2003-10-08 |
| CN1261151C CN1261151C (en) | 2006-06-28 |
Family
ID=28048524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02109347 Expired - Lifetime CN1261151C (en) | 2002-03-24 | 2002-03-24 | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1261151C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101045116B (en) * | 2007-04-18 | 2010-05-26 | 孙晓波 | Traditional Chinese medicine for treating cholecystitis |
| CN102872270A (en) * | 2012-09-25 | 2013-01-16 | 朱风文 | Traditional Chinese medicine for treating chronic cholecystitis |
| CN104771697A (en) * | 2015-04-14 | 2015-07-15 | 青岛辰达生物科技有限公司 | Pharacetuical composition for treating cholecystitis |
| CN104958706A (en) * | 2015-07-21 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Traditional Chinese medicine composition for treating chronic cholecystitis |
-
2002
- 2002-03-24 CN CN 02109347 patent/CN1261151C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101045116B (en) * | 2007-04-18 | 2010-05-26 | 孙晓波 | Traditional Chinese medicine for treating cholecystitis |
| CN102872270A (en) * | 2012-09-25 | 2013-01-16 | 朱风文 | Traditional Chinese medicine for treating chronic cholecystitis |
| CN102872270B (en) * | 2012-09-25 | 2013-12-18 | 朱风文 | Traditional Chinese medicine for treating chronic cholecystitis |
| CN104771697A (en) * | 2015-04-14 | 2015-07-15 | 青岛辰达生物科技有限公司 | Pharacetuical composition for treating cholecystitis |
| CN104958706A (en) * | 2015-07-21 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Traditional Chinese medicine composition for treating chronic cholecystitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1261151C (en) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1857618A (en) | Chinese medicine preparation for reducing sugar | |
| CN101428086B (en) | Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN1824101A (en) | Xingsuerchen medicinal preparation and its new preparation method | |
| CN1748748A (en) | Little leaf deervetch herb preparation for pregnant woman and new preparing method | |
| CN103599343B (en) | A kind of pharmaceutical composition for the treatment of diabetes and its production and use | |
| CN1824160A (en) | Yin nourishing lung clearing medicinal preparation and its new preparation method | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1879701A (en) | Cold-treating medicine and preparation method thereof | |
| CN1181880C (en) | Compound macrostem onion preparation for curing chronic obstructive lung disease and its preparing method | |
| CN1814163A (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN1939480A (en) | Chinese-medicinal compound preparation for treating injury | |
| CN1824270A (en) | Middle-jiao regulating medicinal preparation and its new preparation method | |
| CN1823980A (en) | Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method | |
| CN1049148C (en) | Stomach-recovering capsule | |
| CN1748741A (en) | Little leaf deervetch herb acne removing preparation and new preparing method | |
| CN1876112A (en) | A medicine for treating gastric disease and preparation method thereof | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
| CN1438027A (en) | Chinese medicine for treating breast disease | |
| CN1456198A (en) | Angong hemostatics | |
| CN1907315A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1626210A (en) | Preparation of 'Sanjin' medication for treating diseases of urinary system and preparation method | |
| CN1846753A (en) | Medicine composition for treating hyperuricemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060628 |
|
| RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20100901 |